BioSpace News Archive

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to POMALYST® (pomalidomide) for the treatment of patients with human immunodeficiency virus (HIV)-positive Kaposi sarcoma who have previously received systemic chemotherapy, as well as patients with HIV‐negative Kaposi’s sarcoma.

AGC Biologics, announced the appointment of Christopher Holt as Site Head/General Manager of its Bothell, Washington operations.

Recovery Unplugged Treatment Centers is pleased to announce the arrival of veteran healthcare thought leader and sales executive Angelo Devita, MPH as its new Chief Growth Officer.

Aquestive Therapeutics, Inc. announced that management will present at the 2019 RBC Capital Markets Global Healthcare Conference to be held in New York, NY on May 21-22, and the 20th Annual B.

The Alzheimer’s Clinical Trials Consortium and Eisai Co., Ltd. announced that the investigational oral BACE inhibitor elenbecestat and the investigational anti-amyloid beta protofibril antibody BAN2401, which are currently being evaluated as treatments for early Alzheimer’s disease, have been selected by the ACTC as treatments to be evaluated in upcoming clinical studies targeting primary prevention and secondary prevention of AD.

Continuous R&D investment delivers breakthroughs in upstream sequencing technology

The Permanente Federation announced that Katherine Robinson Saral will join the company as chief legal officer effective May 29, 2019.

To promote OdySight, a digital solution to optimize visual monitoring of patients with chronic eye diseases

AAC Holdings, Inc. announced that on Monday, May 13, 2019 it will unveil a new long-term strategic vision for the Company on a planned conference call.

Strategic investment signals positive response of healthcare community to Theranica’s new approach to migraine management